Aurora Cannabis Inc.
$3.72
▲
2.69%
2026-04-21 05:02:00
www.auroramj.com
NCM: ACB
Explore Aurora Cannabis Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$285.82 M
Current Price
$3.72
52W High / Low
$9.33 / $4.29
Stock P/E
—
Book Value
$6.8
Dividend Yield
—
ROCE
1.34%
ROE
-15.51%
Face Value
—
EPS
$-1.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
—
Beta
1.32
Debt / Equity
17.79
Current Ratio
3.06
Quick Ratio
2.16
Forward P/E
-31.18
Price / Sales
0.52
Enterprise Value
$218.52 M
EV / EBITDA
-6.68
EV / Revenue
0.59
Rating
Buy
Target Price
$6.31
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Organogenesis Holdings Inc. | $2.52 | 8.75 | $324.17 M | — | 11.21% | 9.04% | $7.08 / $2.21 | $2.36 |
| 2. | Biofrontera Inc. | $1.09 | — | $12.81 M | — | -68.08% | -1.41% | $1.19 / $0.54 | $0.9 |
| 3. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 4. | BioXcel Therapeutics, Inc. | $1.2 | — | $32.49 M | — | 557.9% | 74.14% | $8.08 / $1.01 | $-4.28 |
| 5. | Sonoma Pharmaceuticals, Inc. | $2.65 | — | $4.59 M | — | -38.66% | -81.18% | $6.92 / $2 | $1.98 |
| 6. | Amphastar Pharmaceuticals, Inc. | $22.92 | 10.43 | $1.02 B | — | 9.54% | 12.9% | $31.26 / $17.03 | $17.28 |
| 7. | Kiniksa Pharmaceuticals International, plc | $42.46 | 55.07 | $3.25 B | — | 12.37% | 11.73% | $50.03 / $19.62 | $7.44 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 94.19 M | 90.37 M | 98.02 M | 90.54 M | 88.2 M | — |
| Operating Profit | 2.18 M | -18.27 M | -20.22 M | -28.25 M | 32.55 M | — |
| Net Profit | 1.82 M | -51.47 M | -15.21 M | -24.56 M | 28.55 M | — |
| EPS in Rs | 0.03 | -0.91 | -0.27 | -0.43 | 0.5 | -0.23 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 343.29 M | 269.64 M | 221.34 M | 245.25 M |
| Operating Profit | 9.97 M | -31.05 M | -219.38 M | -246.65 M |
| Net Profit | 1.59 M | -69.33 M | -1.72 B | -693.62 M |
| EPS in Rs | 0.03 | -1.22 | -30.29 | -12.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 852.67 M | 838.67 M | 1.08 B | 2.6 B |
| Total Liabilities | 244.07 M | 236.8 M | 422 M | 567.03 M |
| Equity | 567.17 M | 559.77 M | 661.84 M | 2.04 B |
| Current Assets | 478.33 M | 426.61 M | 745.12 M | 665.89 M |
| Current Liabilities | 110.86 M | 124.62 M | 130.86 M | 116.38 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | 16 M | -68.51 M | -110.27 M | -210.58 M |
| Investing CF | -14.33 M | -3.36 M | -36.17 M | -26.91 M |
| Financing CF | -0.12 M | -47.92 M | 147.78 M | 521.95 M |
| Free CF | -2.85 M | -85.34 M | -142.48 M | -263.66 M |
| Capex | -18.86 M | -16.83 M | -32.21 M | -53.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 27.32% | — | -9.75% | — |
| Earnings Growth % | 102.29% | — | -147.63% | — |
| Profit Margin % | 0.46% | -25.71% | -776.02% | -282.82% |
| Operating Margin % | 2.91% | -11.52% | -99.11% | -100.57% |
| Gross Margin % | 54.65% | 48.85% | 9.59% | -8.79% |
| EBITDA Margin % | 14.96% | -4.1% | -702.38% | -218.26% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-02-20 | 1:0.1 |